<DOC>
	<DOCNO>NCT01277094</DOCNO>
	<brief_summary>This multi-center , double-blind , randomize , placebo-controlled study evaluate change liver fat content , pharmacokinetics safety RO5093151 patient non-alcoholic fatty liver disease . Patients randomize receive either daily oral dos RO5093151 match placebo . The anticipated time study treatment 12 week .</brief_summary>
	<brief_title>A Study RO5093151 Patients With Non-Alcoholic Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Adult patient , 3565 year age Hepatic steatosis assess magnetic resonance spectroscopy ( MRS ) liver fat &gt; 5.56 % screen Body mass index ( BMI ) &gt; 27 kg/m2 screen Insulin resistance assess homeostatic model assessmentinsulin resistance ( HOMAIR ) &gt; 2.5 screen Agreement maintain prior diet exercise habit full course study History diabetes mellitus base World Health Organization ( WHO ) criterion Known polycystic ovary syndrome Other liver disease e.g . chronic viral hepatitis , alcoholic liver disease , hemachromatosis , cirrhosis Known autoimmune disease chronic inflammatory disease Myocardial infarction stroke within 6 month prior screen Patients take antidiabetic and/or weightlowering medication currently within previous 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>